Direxion Daily CSI China Internet Bull 2X Shares vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.78 (market cap $173.62M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.74 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 145.5× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| CWEB | RPRX | |
|---|---|---|
Market Cap | $173.62M | $25.27B |
Volume | 551,726 | 3,671,183 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $63.96 |
52-Week Low | $17.39 | $35.44 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
CWEB is trading at $18.02, down 1.85% on the day, with technical indicators showing a bearish trend across moving averages. The stock faces selling pressure with all 13 moving average signals bearish and key resistance levels clustered around $18. Recent news highlights China's AI ambitions and potential growth in China tech stocks as catalysts.
The outlook remains cautious due to technical weakness, though exposure to China's growing AI sector offers long-term potential. Key risks include China market volatility and competitive pressures. Investors should monitor earnings reports for fundamental validation of growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →